research Doxetaxel: new indication. Prostate cancer: a few more weeks.
In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.